Trial
NCT00003511
Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Burzynski Research Institute
Collaborators
—
Condition
Multiple Myeloma
Intervention
Antineoplaston therapy (Atengenal + Astugenal)
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-09